CMG Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
CMG Pharmaceutical has a total shareholder equity of ₩190.2B and total debt of ₩25.6B, which brings its debt-to-equity ratio to 13.4%. Its total assets and total liabilities are ₩242.1B and ₩51.9B respectively. CMG Pharmaceutical's EBIT is ₩3.0B making its interest coverage ratio -0.8. It has cash and short-term investments of ₩68.8B.
Key information
13.4%
Debt to equity ratio
₩25.58b
Debt
Interest coverage ratio | -0.8x |
Cash | ₩68.83b |
Equity | ₩190.23b |
Total liabilities | ₩51.87b |
Total assets | ₩242.10b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A058820's short term assets (₩115.7B) exceed its short term liabilities (₩24.5B).
Long Term Liabilities: A058820's short term assets (₩115.7B) exceed its long term liabilities (₩27.3B).
Debt to Equity History and Analysis
Debt Level: A058820 has more cash than its total debt.
Reducing Debt: A058820's debt to equity ratio has increased from 0% to 13.4% over the past 5 years.
Debt Coverage: A058820's debt is not well covered by operating cash flow (15.3%).
Interest Coverage: A058820 earns more interest than it pays, so coverage of interest payments is not a concern.